Brazil

7 Vaccines Approved for Use in Brazil

RNA

Pfizer/BioNTech

Comirnaty

Approved in 146 countries
80 trials in 26 countries
Approval Source: reuters.com
Non Replicating Viral Vector

Gamaleya

Sputnik V

Approved in 74 countries
24 trials in 7 countries
Approval Source: reuters.com
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Ad26.COV2.S

Approved in 111 countries
23 trials in 23 countries
Approval Source: reuters.com
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 140 countries
63 trials in 30 countries
Approval Source: reuters.com
Non Replicating Viral Vector

Serum Institute of India

Covishield (Oxford/ AstraZeneca formulation)

Approved in 49 countries
3 trials in 1 country
Approval Source: bio.fiocruz.br
Inactivated

Sinopharm (Beijing)

Covilo

Approved in 91 countries
29 trials in 12 countries
Approval Source: gov.br
Inactivated

Sinovac

CoronaVac

Approved in 56 countries
37 trials in 9 countries
Approval Source: apnews.com

13 in Clinical Trials in Brazil

Protein Subunit

Clover

SCB-2019

12 trials in 11 countries
VLP

Medicago

Covifenz

Approved in 1 country
6 trials in 6 countries
DNA

Inovio

INO-4800

9 trials in 9 countries
RNA

Pfizer/BioNTech

Comirnaty

Approved in 146 countries
80 trials in 26 countries
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Ad26.COV2.S

Approved in 111 countries
23 trials in 23 countries
Non Replicating Viral Vector

Oxford/AstraZeneca

AZD2816

2 trials in 2 countries
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 140 countries
63 trials in 30 countries
Non Replicating Viral Vector

ReiThera

GRAd-COV2

5 trials in 12 countries
Inactivated

Chinese Academy of Medical Sciences

Inactivated (Vero Cells)

8 trials in 4 countries
Inactivated

Sinovac

CoronaVac

Approved in 56 countries
37 trials in 9 countries
Non Replicating Viral Vector

Mahidol University

NDV-HXP-S

7 trials in 3 countries
Protein Subunit

University of Saskatchewan

COVAC-1

RNA

SENAI CIMATEC

HDT-301